Urinary Bladder, Neurogenic, Urinary Bladder, Overactive
Conditions
Brief summary
This study will describe the prescription conditions of botulinum toxin Type A (Botox®) injection for the treatment of urinary incontinence due to neurogenic detrusor overactivity (NDO) or idiopathic overactive bladder (IOAB) as per standard of care in clinical practice in France.
Interventions
BIOLOGICALbotulinum toxin Type A
Botulinum toxin Type A (Botox®) injection as prescribed as standard of care in clinical practice.
Sponsors
Allergan
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
-Patients who receive a Botox® injection for urinary incontinence.
Exclusion criteria
-Patients not residing in France.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Target Patients Prescribed Botox® in Clinical Practice | Day 1 |
Secondary
| Measure | Time frame |
|---|---|
| Characteristics of Patients | Day 1 |
| Number of Patients by Pathology History | Day 1 |
| Number of Patients by Medical and Surgical History | Day 1 |
| Reduction of Number of Daily Urinary Incontinence Episodes in Non-naive Patients | Day 1 |
| Percentage of Continent Patients in Non-naive Patients | Day 1 |
| Treatments Previously Prescribed | Day 1 |
| Number of Sites Injected | Day 1 |
| Characteristics of Injector Physicians | Day 1 |
| Types of Anaesthesia and Antibiotic Prophylaxis Used | Day 1 |
| Cytobacteriological Examination of the Urine | Day 1 |
| Total Number of Botox® Cycles in Non-naive Patients (previously received Botox®) | Day 1 |
| Length of Botox® Treatment in Non-naive Patients | Day 1 |
| Time Since Last Botox® Injection in Non-naive Patients | Day 1 |
| Characteristics of Injector Sites (Locations) | Day 1 |
| Number of Adverse Events during the Visit | Day 1 |
| Total Dose of Botox® Used | Day 1 |
Countries
France
Outcome results
None listed